{"id":8498,"date":"2010-06-22T11:27:11","date_gmt":"2010-06-22T15:27:11","guid":{"rendered":"http:\/\/asweetlife.org\/?p=8498"},"modified":"2015-12-29T08:39:38","modified_gmt":"2015-12-29T13:39:38","slug":"novo-nordisk-re-initiates-phase-3-development-of-liraglutide-victoza-for-obesity-treatment","status":"publish","type":"post","link":"https:\/\/asweetlife.org\/?p=8498","title":{"rendered":"Novo Nordisk Re-Initiates Phase 3 Development of Liraglutide (Victoza) for Obesity Treatment"},"content":{"rendered":"<p style=\"text-align: justify;\"><a href=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/06\/NovoNordiskLogo.jpg\" rel=\"mfp\"><img decoding=\"async\" class=\"alignleft size-full wp-image-8002 lazyload\" style=\"margin: 4px;\" title=\"NovoNordiskLogo\" src=\"data:image\/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==\" data-src=\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/06\/NovoNordiskLogo.jpg\" alt=\"\" width=\"172\" height=\"128\" \/><\/a>Novo Nordisk today announced the decision to re-initiate the global phase 3 development program of liraglutide for the treatment of obesity.<\/p>\n<p>Following the US approval of Victoza for the treatment of type 2 diabetes, Novo Nordisk has been in dialogue with the FDA regarding the further progression of the development program investigating the potential of liraglutide within obesity. Based on the feedback from the FDA, Novo Nordisk now plans to re-initiate the global phase 3 program in the first half of 2011 in clinical trials comprising approximately 5,000 patients.<\/p>\n<p>Novo Nordisk remains committed to the development of a longer-acting GLP-1 analogue and now expects to outline the clinical development strategy for semaglutide, a once-weekly GLP-1 analogue, and the once-weekly version of liraglutide in the second half of 2011.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk today announced the decision to re-initiate the global phase 3 development program of liraglutide for the treatment of obesity.<br \/>\nFollowing the US approval of Victoza for the treatment of type 2 diabetes, Novo Nordisk has been in dialogue with the FDA regarding the further progression of the development program investigating&#8230;<\/p>\n","protected":false},"author":131,"featured_media":29442,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[1443],"tags":[230,315],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.9 (Yoast SEO v22.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Novo Nordisk Victoza (Liraglutide) for Obesity Treatment - Phase 3 Development Re-Initiated<\/title>\n<meta name=\"description\" content=\"Novo Nordisk today announced the decision to re-initiate the global phase 3 development program of liraglutide for the treatment of obesity.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/asweetlife.org\/?p=8498\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"ASweetLife Team\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/asweetlife.org\/?p=8498\",\"url\":\"https:\/\/asweetlife.org\/?p=8498\",\"name\":\"Novo Nordisk Victoza (Liraglutide) for Obesity Treatment - Phase 3 Development Re-Initiated\",\"isPartOf\":{\"@id\":\"https:\/\/asweetlife.org\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/asweetlife.org\/?p=8498#primaryimage\"},\"image\":{\"@id\":\"https:\/\/asweetlife.org\/?p=8498#primaryimage\"},\"thumbnailUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/06\/Novo-Nordisk-Logo.png\",\"datePublished\":\"2010-06-22T15:27:11+00:00\",\"dateModified\":\"2015-12-29T13:39:38+00:00\",\"author\":{\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\"},\"description\":\"Novo Nordisk today announced the decision to re-initiate the global phase 3 development program of liraglutide for the treatment of obesity.\",\"breadcrumb\":{\"@id\":\"https:\/\/asweetlife.org\/?p=8498#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/asweetlife.org\/?p=8498\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/?p=8498#primaryimage\",\"url\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/06\/Novo-Nordisk-Logo.png\",\"contentUrl\":\"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/06\/Novo-Nordisk-Logo.png\",\"width\":215,\"height\":160,\"caption\":\"Novo Nordisk Logo\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/asweetlife.org\/?p=8498#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/asweetlife.org\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk Re-Initiates Phase 3 Development of Liraglutide (Victoza) for Obesity Treatment\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/asweetlife.org\/#website\",\"url\":\"https:\/\/asweetlife.org\/\",\"name\":\"ASweetLife\",\"description\":\"The Diabetes Magazine\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/asweetlife.org\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585\",\"name\":\"ASweetLife Team\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/asweetlife.org\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g\",\"caption\":\"ASweetLife Team\"},\"url\":\"https:\/\/asweetlife.org\/?author=131\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk Victoza (Liraglutide) for Obesity Treatment - Phase 3 Development Re-Initiated","description":"Novo Nordisk today announced the decision to re-initiate the global phase 3 development program of liraglutide for the treatment of obesity.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/asweetlife.org\/?p=8498","twitter_misc":{"Written by":"ASweetLife Team","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/asweetlife.org\/?p=8498","url":"https:\/\/asweetlife.org\/?p=8498","name":"Novo Nordisk Victoza (Liraglutide) for Obesity Treatment - Phase 3 Development Re-Initiated","isPartOf":{"@id":"https:\/\/asweetlife.org\/#website"},"primaryImageOfPage":{"@id":"https:\/\/asweetlife.org\/?p=8498#primaryimage"},"image":{"@id":"https:\/\/asweetlife.org\/?p=8498#primaryimage"},"thumbnailUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/06\/Novo-Nordisk-Logo.png","datePublished":"2010-06-22T15:27:11+00:00","dateModified":"2015-12-29T13:39:38+00:00","author":{"@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585"},"description":"Novo Nordisk today announced the decision to re-initiate the global phase 3 development program of liraglutide for the treatment of obesity.","breadcrumb":{"@id":"https:\/\/asweetlife.org\/?p=8498#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/asweetlife.org\/?p=8498"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/?p=8498#primaryimage","url":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/06\/Novo-Nordisk-Logo.png","contentUrl":"https:\/\/asweetlife.org\/wp-content\/uploads\/2010\/06\/Novo-Nordisk-Logo.png","width":215,"height":160,"caption":"Novo Nordisk Logo"},{"@type":"BreadcrumbList","@id":"https:\/\/asweetlife.org\/?p=8498#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/asweetlife.org\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk Re-Initiates Phase 3 Development of Liraglutide (Victoza) for Obesity Treatment"}]},{"@type":"WebSite","@id":"https:\/\/asweetlife.org\/#website","url":"https:\/\/asweetlife.org\/","name":"ASweetLife","description":"The Diabetes Magazine","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/asweetlife.org\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/5de2b093878b82b0ea97917f8fd72585","name":"ASweetLife Team","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/asweetlife.org\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ba76b5c6c27d32738b13f9a8a5cfcf02?s=96&d=mm&r=g","caption":"ASweetLife Team"},"url":"https:\/\/asweetlife.org\/?author=131"}]}},"_links":{"self":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/8498"}],"collection":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/users\/131"}],"replies":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8498"}],"version-history":[{"count":0,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/posts\/8498\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=\/wp\/v2\/media\/29442"}],"wp:attachment":[{"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8498"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8498"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/asweetlife.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8498"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}